Two neuroplastogens. Two mechanisms. One indication. We ran them both through Warning Flags™, our visual risk estimator for psychedelic and neuroplastogen development.
Two of the most closely watched NCEs in neuropsychiatry are now in clinical development for major depressive disorder. Zalsupindole (DLX-001), developed by Delix Therapeutics, is a non-hallucinogenic 5-MeO-DMT analog that promotes cortical neuroplasticity through serotonergic signaling. Blixeprodil (GM-1020), developed by Gilgamesh Pharma, is a first-in-class oral non-competitive NMDA receptor antagonist. Both are true NCEs with composition-of-matter IP. Both target MDD. They represent different approaches to treating the same problem.
We ran both zalsupindole and blixeprodil through Warning Flags Head-to-Head NCE Edition, which evaluates risk across seven categories and maps each program to a composite score from 0 to 66+ using public and available data on both programs. Zalsupindole scored 7.8 (Yellow flag: caution, manageable risk). Blixeprodil scored 4.0 (Green / Striped flag: clear conditions with minor considerations).
Delix completed a Phase 1b study in 18 MDD patients (October 2025). Both cohorts showed a 12-point MADRS reduction at Day 8, roughly 50% improvement from baseline, sustained through Day 36. No serious adverse events. The FDA cleared a Phase 2 protocol with three arms, at-home self-administration, and an adaptive interim analysis.
Gilgamesh completed a Phase 2a in 46 MDD patients (January 2026). The study had two parts. Part A used a placebo-controlled crossover design, in which each patient receives both drug and placebo in separate periods and serves as their own control. At a single dose of 140 mg, blixeprodil produced a 6.3-point MADRS reduction versus placebo at 24 hours (p = 0.006, effect size 0.85). By Day 8, the difference narrowed to 5.1 points and missed statistical significance (p = 0.076). The drug's effect persisted into the placebo period, so the crossover comparison could only be drawn from the first dosing period. Gilgamesh had anticipated this in the analysis plan. In Part B, patients received twice-weekly dosing for two weeks at 140 or 210 mg. Remission rate across both dose groups was 53% at Day 42, and effects held through 28 days of follow-up.
Both programs produced encouraging early data. But blixeprodil has placebo-controlled efficacy with statistical significance at 24 hours. Zalsupindole has open-label signals and biomarker data but no placebo comparison yet.
“The gap between zalsupindole and blixeprodil is a gap of maturity, not of quality.”
The 3.8-point gap comes from three areas. First, translational confidence. Blixeprodil benefits from the esketamine precedent. The NMDA pathway is validated at the human level for depression. Zalsupindole's neuroplastogen mechanism is novel. No drug in this class has been approved. Second, the accumulation of moderate flags in our model. Neither program carries critical findings. Blixeprodil has 2 high-level and 12 medium-level flags. Zalsupindole has 1 high-level and 20 medium-level flags. The volume of moderate considerations, not the presence of severe ones, widens the score. Third, financial position. Gilgamesh closed a $60 million Series A in March 2026. Delix has raised $100 million total but with a Phase 2 to fund, the model flags dilution risk and moderate runway.
Blixeprodil's advantages are structural: mechanistic precedent, placebo-controlled Phase 2a data, a complete GLP toxicology package, and a stronger balance sheet. Zalsupindole's advantages are different in kind. Delix invested in translational biomarkers (qEEG, polysomnography) that most competitors lack entirely. Blixeprodil has no public biomarker program. Delix also secured FDA clearance for at-home self-administration, an unusual signal for a CNS compound derived from a psychedelic scaffold. And zalsupindole has a published selectivity profile showing minimal off-target liability. Blixeprodil's selectivity panel has not been disclosed.
Blixeprodil has a lower risk profile today. Zalsupindole has a differentiated clinical strategy with regulatory signals that support its safety case. The gap between them is a gap of maturity, not of quality. Both are competitive programs. Neither has a pharma partner. Both may need one before pivotal trials.
Warning Flags™ is a proprietary risk scoring model developed by Cascades Analytics. Scores reflect publicly available information as of May 2026. This analysis is not investment advice.
References
- Delix Therapeutics press release, October 28, 2025. "Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At-Home Administration." BusinessWire. (Phase 1b data, MADRS results, FDA Phase 2 clearance, trial design.)
- Salfiti et al. (2026). ACS Chemical Neuroscience. Pharmacological profiling of zalsupindole. (Selectivity profile, serotonergic target engagement, neuroplasticity comparison to ketamine/psilocybin/DMT.)
- Delix Therapeutics, Tracxn company profile. $100M total raised, 25 employees, Series A $70M (September 2021).
- Gilgamesh Pharma press release, January 6, 2026. "Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder." PRNewswire. (46 patients, MADRS LS mean difference, p-values, effect sizes, remission rate, crossover carryover, dosing regimens.)
- Gilgamesh Pharma press release, March 24, 2026. "Gilgamesh Pharma Closes Oversubscribed $60 Million Series A." PRNewswire. (Series A, AbbVie acquisition context, pipeline.)
- Synapse / PatSnap drug profile, April 2026. Blixeprodil (GM-1020). (AbbVie acquisition of Gilgamesh Pharmaceuticals for up to $1.2B, spinout context, management continuity.)
- Spravato (esketamine) FDA approval, March 2019. NMDA receptor antagonism for treatment-resistant depression. (Regulatory precedent for blixeprodil's mechanism class.)